obsessive-compulsive disorder (OCD)

article

Nucleic acid therapy accelerator

23 November 2023 | By Ellen Capon (Drug Target Review)

Dr William Schafer, of the MRC Laboratory of Molecular Biology, focuses on the cellular and molecular mechanisms of behaviour, which is one of the fundamental problems of biology. Schafer and his colleagues have studied the nematode Caenorhabditis elegans, using a variety of approaches such as optogenetic neuroimaging and high content…

news

Brain recordings could improve deep brain stimulation therapy for OCD

21 December 2021 | By Anna Begley (Drug Target Review)

Scientists captured more than 1,000 hours of brain recordings from obsessive compulsive disorder (OCD) patients and uncovered candidate neurological signatures.

news

Exome sequencing reveals genetic drug target for OCD

29 June 2021 | By Victoria Rees (Drug Target Review)

Following a whole exome sequencing study, researchers have found that mutations in the SLITRK5 gene could be targeted by drugs to treat OCD.

news

Novel antibody treatment for OCD demonstrates efficacy in mice

22 April 2020 | By Victoria Rees (Drug Target Review)

Researchers who administered an antibody to neutralise an OCD-associated protein in mice found it reduced their anxious behaviours.

article

Discovering and designing drugs with artificial intelligence

4 March 2020 | By Victoria Rees (Drug Target Review)

The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.